Commentary Article Ever-Evolving landscape of biosimilars in Canada; findings and implications
from a global perspective Brian G Page 1 1 Commentary Article Ever-Evolving landscape of …

Recent reports related to in utero exposure of marketed immunosuppressive biologics led to
clinical recommendations to delay live vaccinations for infants due to the concern of reduced …

Introduction In healthcare policy and economic literature, research on the health technology
assessment (HTA) of complex interventions (CIs) is becoming increasingly important. In …

Background Regulatory authorities register medicines for patients to access them within a
reasonable period of time. There is a paucity of available data regarding the extent to which …

The increasing use of lower-cost multiple sourced medicines (generics) and biosimilars are
essential to attain or retain universal healthcare in the face of continual pressure on …

ABSTRACT Objectives Budget Impact Analyses (BIA) of medicines helps managers in
promoting health systems' sustainability when assessing the role and value of new …

Background This study's objective was to demonstrate pharmacokinetic (PK) similarity and
safety of denosumab biosimilar, CT‑P41, and United States–licensed reference denosumab …

COMMENTARY: LOCAL POLICIES ON BIOSIMILARS - ARE THEY DESIGNED TO OPTIMIZE
USE OF FREED RESOURCES; findings and implications? Page 1 This is a peer-reviewed …

Objective We aimed to examine managed entry agreement (MEA) methods and their
relation to nationwide drug reimbursement policy goals in the context of the Hungarian …

Psoriatic arthritis (PsA) is a complex, heterogeneous disease, with disease activity in various
domains. In recent years, many novel treatments with diverse mechanisms of action have …